Updates

Quantum Pharma - Five more products now approved

November 2015

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

There’s been a bit of a stock overhang in the shares recently but it seems to be slowly lifting as Legal & General has just popped up with a 9.2% holding. This followed Quantum’s H1 results showing sales up 22% to £34.3m, adjusted pretax profit up 77% at £4.5m and eps up from 1.5p to 3.2p. The company has also declared a first ever interim dividend of 0.5p.Following two acquisitions in the period of NuPharm and Lambda, these results were presented with new segmental reporting across three divisions; specials, niche pharmaceuticals and medical adherence.The core specials arm continued to trade well in a market where prescribing volumes were down but still managed to record sales up by 13% to £ ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Scapa

Mothercare

Quantum Pharma - Gain since our February write up: 75% (October 2017)

Quantum Pharma - Bid from Clinigen (September 2017)

Quantum Pharma (June 2017)

Quantum Pharma - Considerably less flannel from new CEO (February 2017)

Quantum Pharma - Sweep of board and placing (November 2016)

Quantum Pharma (June 2016)

Quantum Pharma (March 2016)

Quantum Pharma - Soon-to-be prospective PE of 9.9 (October 2015)

Quantum Pharma (September 2015)

Quantum Pharma - Explosive growth trajectory (June 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X